×
Please click
here
if you are not redirected within a few seconds.
All
Images
News
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
PR Newswire
PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people...
1 week ago
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
Yahoo Finance
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...
5 days ago
Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations
Yahoo Finance
Akebia Therapeutics ( NASDAQ:AKBA ) First Quarter 2024 Results Key Financial Results Revenue: US$32.6m (down 19% from...
1 week ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted...
2 weeks ago
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript May 9, 2024 Akebia Therapeutics, Inc. beats earnings expectations.
1 week ago
Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
Yahoo Finance
Insights into Akebia Therapeutics' Performance and Strategic Developments.
1 week ago
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney ...
PR Newswire
The approval of Vafseo for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months is based on...
1 month ago
Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
Yahoo Finance
The analysts covering Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) delivered a dose of negativity to shareholders today...
1 week ago
Akebia Secures $55 Million Term Loan Financing
PR Newswire
(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has...
3 months ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). Akebia Therapeutics, Inc. (Nasdaq: AKBA), a...
1 month ago